Saturday 17 October 2026
Export GPCR’s income statement to Excel — free account
Structure Therapeutics Inc. Sponsored ADR
GPCR Healthcare Biotechnology
In the quarter to June 2026, EPS fell 36.4% and free cash flow fell 119.2%, each against the same quarter a year earlier.
20.95
1.24
−5.59%
Follow GPCR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (20.21%) | (15.00%) | (11.86%) | (25.28%) |
+8 more TTM periods Free account |
|
| (19.17%) | (14.35%) | (11.35%) | (23.87%) | ||
ROIC |
(1,371.78%) | 0.00% | (157.24%) | 0.00% | |
Return on Tangible Assets |
(16.37%) | (11.83%) | (9.33%) | (27.68%) | |
Average Days of Receivables |
— | — | 0.00 | — | |
Free Cash Flow per Share |
(3.09) | (2.20) | (3.81) | (3.36) | |
Free Cash Flow |
(224.50) | (159.22) | (225.81) | (196.38) | |
Capital Expenditures |
(4.21) | (4.48) | (3.61) | (2.13) | |
| Other line items | |||||
Cash ROIC |
(8.32%) | (5.48%) | (7.62%) | (12.52%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.03 | 0.91 | 1.57 | 0.92 | |
Depreciation/Fixed assets |
0.81 | 0.62 | 0.25 | 0.17 | |
Capex/Depreciation |
(0.82) | (1.14) | (2.15) | (2.63) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.03) | (2.14) | (3.75) | (3.32) | |
Capex per Share |
(0.06) | (0.06) | (0.06) | (0.04) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates